Target type: biologicalprocess
Any process that modulates the size of a metanephric kidney. [GOC:bf]
The metanephros, the precursor of the adult kidney, undergoes precise size regulation during development. This intricate process involves a complex interplay of signaling pathways, transcription factors, and cellular interactions. Here's a detailed description of the key elements involved:
**1. Growth Factors and Signaling Pathways:**
* **Wnt signaling:** This pathway plays a crucial role in metanephros growth. Wnt ligands, produced by the ureteric bud (UB), stimulate proliferation of the metanephric mesenchyme (MM) cells, which give rise to nephrons, the functional units of the kidney.
* **FGF signaling:** Fibroblast growth factors (FGFs), specifically FGF2, promote branching morphogenesis of the UB and interact with Wnt signaling to regulate MM proliferation.
* **BMP signaling:** Bone morphogenetic proteins (BMPs), particularly BMP4, act as negative regulators of metanephros size. They restrict MM proliferation and induce differentiation of the UB epithelium.
**2. Transcription Factors:**
* **Six2:** This transcription factor is essential for maintaining the proliferative state of MM cells and preventing premature differentiation. Six2 expression is downregulated as MM cells differentiate into nephrons, contributing to size control.
* **Pax2:** This transcription factor is involved in both UB and MM development and is necessary for normal metanephros size.
* **Eya1:** This transcription factor collaborates with Six2 to regulate MM proliferation and differentiation.
* **Cited1:** This transcription factor acts downstream of Wnt signaling and promotes MM cell survival and proliferation.
**3. Cellular Interactions and Morphogenesis:**
* **UB-MM interactions:** The close interactions between the UB and MM are crucial for metanephros development. The UB secretes signals that induce MM proliferation and differentiation, while the MM provides signals that regulate UB branching.
* **Branching morphogenesis:** The UB undergoes intricate branching, creating a network of collecting ducts that connect to the nephrons. This branching process is tightly regulated and contributes to the final size of the kidney.
* **Nephron formation:** The MM cells differentiate into nephrons, the functional units of the kidney. This process involves a complex series of events, including condensation, epithelialization, and tubule formation.
**4. Negative Feedback Mechanisms:**
* **Negative feedback loops:** The metanephros development is regulated by negative feedback loops that ensure appropriate size and prevent overgrowth. For instance, the expression of BMP4 is upregulated as the metanephros grows, acting as a brake on further MM proliferation.
**5. Genetic and Environmental Factors:**
* **Genetic mutations:** Mutations in genes involved in the above pathways can lead to abnormalities in metanephros size, causing various kidney diseases.
* **Environmental factors:** Factors like maternal nutrition and exposure to toxins can also influence metanephros development and contribute to kidney size variations.
In summary, regulation of metanephros size is a highly orchestrated process involving a delicate balance of multiple signaling pathways, transcription factors, and cellular interactions. Precise coordination of these factors ensures the development of a functional kidney of appropriate size.'
"
Protein | Definition | Taxonomy |
---|---|---|
Type-2 angiotensin II receptor | An angiotensin II receptor 2 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P50052] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
5-iodo-2-(oxaloamino)benzoic acid | organoiodine compound | ||
candesartan | candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension. candesartan: a nonpeptide angiotensin II receptor antagonist | benzimidazolecarboxylic acid; biphenylyltetrazole | angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic |
avapro | irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease. | azaspiro compound; biphenylyltetrazole | angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic |
losartan | losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II. | biphenylyltetrazole; imidazoles | angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist |
miconazole | 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 2,4-dichlorobenzyl group. miconazole : A racemate composed of equimolar amounts of (R)- and (S)-miconazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes. Miconazole: An imidazole antifungal agent that is used topically and by intravenous infusion. | dichlorobenzene; ether; imidazoles | |
ipsapirone | N-arylpiperazine | ||
flesinoxan | |||
valsartan | valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity. Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION. | biphenylyltetrazole; monocarboxylic acid; monocarboxylic acid amide | angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic |
telmisartan | telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension. Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION. | benzimidazoles; biphenyls; carboxybiphenyl | angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic |
bexarotene | benzoic acids; naphthalenes; retinoid | antineoplastic agent | |
exp7711 | EXP7711: to search, use E#P7711(nm); angiotensin II receptor antagonist; structure given in first source | ||
bibs 39 | BIBS 39: structure given in first source; angiotensin II receptor antagonist | ||
a 81988 | A 81988: angiotensin II antagonist selective for type 1 receptors | ||
bibs 222 | BIBS 222: structure given in first source; angiotensin II receptor antagonist | ||
chrysamine g | chrysamine G: structure given in first source; RN refers to disodium salt | ||
angiotensin ii | Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V). | amino acid zwitterion; angiotensin II | human metabolite |
l 158809 | L 158809: RN & structure given in first source; angiotensin receptor antagonist | ||
2-(oxaloamino)benzoic acid | (oxaloamino)benzoic acid | ||
alitretinoin | Alitretinoin: A retinoid that is used for the treatment of chronic hand ECZEMA unresponsive to topical CORTICOSTEROIDS. It is also used to treat cutaneous lesions associated with AIDS-related KAPOSI SARCOMA. | retinoic acid | antineoplastic agent; keratolytic drug; metabolite; retinoid X receptor agonist |
tak 013 | |||
pd 123319 | PD123319 : An imidazopyridine consisting of 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine having 4-(dimethylamino)-3-methylbenzyl, diphenylacetyl and carboxy and groups at positions 1, 5 and 6 respectively | imidazopyridine | angiotensin receptor antagonist; endothelin receptor antagonist; vasoconstrictor agent |
exp 655 | |||
saralasin | Saralasin: An octapeptide analog of angiotensin II (bovine) with amino acids 1 and 8 replaced with sarcosine and alanine, respectively. It is a highly specific competitive inhibitor of angiotensin II that is used in the diagnosis of HYPERTENSION. | oligopeptide | |
l 162313 | L 162313: a biphenylimidazole derivative; a non-peptide angiotensin agonist; no further information available 2/95 | ||
l 163491 | L 163491: structure given in first source | ||
nrx 194204 | IRX4204: retinoid X receptor (RXR) agonist; structure in first source | ||
agn 194204 | AGN 194204: a retinoid X receptor ligand; structure in first source | ||
ema401 | |||
naluzotan | naluzotan: an antidepressant and anti-anxiety agent; structure in first source |